Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients
NCT ID: NCT01200407
Last Updated: 2021-08-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
615 participants
OBSERVATIONAL
2010-06-09
2014-01-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Amlodipine as add-on to Olmesartan in Hypertension
NCT00220220
Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab
NCT04120753
Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension
NCT00527514
Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension
NCT00185133
Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia
NCT05660135
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Filipino Hypertensive patients
Male and Female, 18 to 65 year old Filipino hypertensive patients prescribed by their doctors with Normetec
Amlodipine + Olmesartan medoxomil
start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amlodipine + Olmesartan medoxomil
start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lorma Medical Center
San Fernando City, LA Union, Philippines
Holy Child Hospital
Taclobo, Dumaguete City, Negros Oriental, Philippines
Private Clinic
Albay, , Philippines
Private Clinic
Angono, , Philippines
Pines City Doctors Hospital
Baguio City, , Philippines
Private Clinic
Baguio City, , Philippines
Private Clinic
Bulacan, , Philippines
Private Clinic
Calamba, , Philippines
Private Clinic
Cavite, , Philippines
Private Clinic
Cebu, , Philippines
Private Clinic
Cebu City, , Philippines
Private Clinic
City of Muntinlupa, , Philippines
Private Clinic
City of Taguig, , Philippines
Private Clinic
Dagupan, , Philippines
Private Clinic
Davao City, , Philippines
Private Clinic
Eastwood, , Philippines
Private Clinic
Iloilo City, , Philippines
Private Clinic
Isabela, , Philippines
Private Clinic
Kalibo Aklan, , Philippines
Private Clinic
Laguna, , Philippines
Private Clinic
Laoag, , Philippines
Jesus Nazarene General Hospital
Lingayen, Pangasinan, , Philippines
Private Clinic
Makati, , Philippines
Makati Medical Center
Makati City, , Philippines
Private Clinic
Makati City, , Philippines
Private Clinic
Mandaluyong, , Philippines
Healthway Medical Clinic
Manila, , Philippines
Isaac and Catalina Medical Center
Manila, , Philippines
Metropolitan Medical Center Institutional Review Board
Manila, , Philippines
Metropolitan Medical Center
Manila, , Philippines
Private Clinic
Manila, , Philippines
The Medical City
Manila, , Philippines
Private Clinic
Marikina City, , Philippines
Private Clinic
Metro Manila, , Philippines
Private Clinic
Nueva Vizcaya, , Philippines
Private Clinic
Olongapo City, , Philippines
Private Clinic
Pampanga, , Philippines
Private Clinic
Paranaque City, , Philippines
Private Clinic
Pasay, , Philippines
Private cCinic
Pasig, , Philippines
Private Clinic
Pasig, , Philippines
Dr. Agnes Vargas
Pasig Ciy, , Philippines
Private Clinic
Puerto Princesa City, , Philippines
Armed Forces of the Philippines Medical Center
Quezon City, , Philippines
Private Clinic
Quezon City, , Philippines
Angono Medics
Rizal, , Philippines
Private Clinic
San Juan City, , Philippines
Private Clinic
Tacloban City, , Philippines
Private Clinic
Tarlac City, , Philippines
Private Clinic
Tugegarao, , Philippines
Priavte Clinic
Tuguegarao City, , Philippines
Private Clinic
Tuguegarao City, , Philippines
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B1581001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.